Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Saved in:
| Title: | Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. |
|---|---|
| Authors: | Muhsen IN; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX., Roloff GW; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL., Faramand R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Othman T; Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA., Valtis Y; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York City, NY., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA., Dekker SE; Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA., Connor M; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Mercadal S; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., O'Connor TE; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Dykes KC; Division of Hematology and Oncology, Department of Medicine, University of California San Diego, La Jolla, CA., Ahmed M; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Sutherland KC; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., Gupta VK; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., Majhail N; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, HCA Healthcare, Nashville, TN., Battiwalla M; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, HCA Healthcare, Nashville, TN., Solh MM; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA., Malik SA; Center for Blood Cancer and Oncology, Texas Transplant Institute, Austin, TX., Mathews J; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer, Dallas, TX., Oliai CH; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., Shaughnessy P; Department of Transplant and Cellular Therapy, Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX., Mountjoy L; Department of Lymphoma, Colorado Blood Cancer Institute, Denver, CO., Lee CJ; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT., Logan AC; Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA., Tsai SB; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Leonard JT; Division of Hematology-Oncology, Oregon Health & Science University, Portland, OR., Schwartz M; Department of Hematology and Oncology, University of Colorado, Aurora, CO., Sasine JP; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA., Kumaran M; Department of Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR., Frey N; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York City, NY., Koura D; Division of Hematology and Oncology, Department of Medicine, University of California San Diego, La Jolla, CA., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center and University of Washington School of Medicine, Seattle, WA., Shah BD; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL., Aldoss I; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX. |
| Source: | Blood advances [Blood Adv] 2025 Aug 26; Vol. 9 (16), pp. 4081-4089. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
